The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global myelofibrosis treatment market reached a value of US$ XX Million in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Myelofibrosis is a chronic leukemia disease that affects the blood-forming tissues in the body. It increases the risk of bleeding, which leads to extensive scarring in bone marrow, severe anemia, weakness, and fatigue. It can be diagnosed using physical examination, blood tests, bone marrow tests, imaging tests, and human leukocyte antigen (HLA) typing. At present, various methods of treating myelofibrosis are available, depending on the patients’ symptoms and circumstances. These methods include targeted drug therapy, chemotherapy, surgical interventions, radiation therapy, and stem cell transplantation. In addition, several drugs are being introduced that aid in reducing blood volume and providing relief from different signs and symptoms of the disease.
Factors like thrombocythemia, polycythemia vera, and exposure to industrial chemicals and high levels of radiation can increase the risk of myelofibrosis. As a result, the rising occurrence of these risk factors among a significant part of the population represents one of the key factors impelling the market growth. Moreover, as primary myelofibrosis is the most diagnosed disease among people of 50 years and above, the growing geriatric population and improving diagnostic modalities are positively influencing the demand for myelofibrosis treatment methods worldwide. Apart from this, increasing sales of new drugs that can assist in relieving chronic signs and symptoms of patients are driving the market. For instance, Janus kinase (JAK) inhibitors can lessen the symptoms of an enlarged spleen, night sweats, itching, and bone pain, while immunomodulators help in the normal functioning of the immune system. Furthermore, the increasing investments in research and development (R&D) activities are anticipated to advance the knowledge of myelofibrosis disease and its treatment options and impel the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global myelofibrosis treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on drug type, treatment type and end user.
Breakup by Drug Type:
Breakup by Treatment Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AllCells LLC, American Type Culture Collection Inc, Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Incyte Corporation, Merck & Co. Inc. and Novartis AG.
|Base Year of the Analysis||2020|
|Segment Coverage||Drug Type, Treatment Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AllCells LLC, American Type Culture Collection Inc, Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Incyte Corporation, Merck & Co. Inc. and Novartis AG.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at